A detailed history of Pdt Partners, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 181,803 shares of VERV stock, worth $827,203. This represents 0.09% of its overall portfolio holdings.

Number of Shares
181,803
Previous 333,864 45.55%
Holding current value
$827,203
Previous $1.63 Million 46.04%
% of portfolio
0.09%
Previous 0.17%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.4 - $7.86 $669,068 - $1.2 Million
-152,061 Reduced 45.55%
181,803 $879,000
Q2 2024

Aug 15, 2024

BUY
$4.76 - $12.79 $681,898 - $1.83 Million
143,256 Added 75.16%
333,864 $1.63 Million
Q1 2024

May 15, 2024

BUY
$10.81 - $17.96 $1.3 Million - $2.15 Million
119,979 Added 169.87%
190,608 $2.53 Million
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $624,360 - $1.32 Million
70,629 New
70,629 $984,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $273M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.